miR-181a overexpression predicts the poor treatment response and early-progression of serous ovarian cancer patients.
Panoutsopoulou K, Avgeris M, Magkou P, Mavridis K, Dreyer T, Dorn J, Obermayr E, Reinthaller A, Michaelidou K, Mahner S, Vergote I, Loverix L, Braicu I, Sehouli J, Zeillinger R, Magdolen V, Scorilas A.
Panoutsopoulou K, et al.
Int J Cancer. 2020 Dec 15;147(12):3560-3573. doi: 10.1002/ijc.33182. Epub 2020 Aug 1.
Int J Cancer. 2020.
PMID: 32621752